Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 12436

1.

[Role of magnetic resonance imaging in preoperative assessement of hilar cholangiocarcinoma].

Toumi N, Abid H, Henchir S, Harbi H, Affes N, Ben Mahfoudh K.

Presse Med. 2018 Sep 14. pii: S0755-4982(18)30292-6. doi: 10.1016/j.lpm.2018.06.012. [Epub ahead of print] French.

PMID:
30224216
2.

The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma.

Cloyd JM, Prakash L, Vauthey JN, Aloia TA, Chun YS, Tzeng CW, Kim MP, Lee JE, Katz MHG.

Am J Surg. 2018 Sep 6. pii: S0002-9610(18)30811-0. doi: 10.1016/j.amjsurg.2018.08.024. [Epub ahead of print]

PMID:
30224070
3.

Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma.

Beal EW, Tumin D, Moris D, Zhang XF, Chakedis J, Dilhoff M, Schmidt CM, Pawlik TM.

Hepatobiliary Surg Nutr. 2018 Aug;7(4):270-276. doi: 10.21037/hbsn.2018.03.16.

4.

Effectiveness of additional resection of the invasive cancer-positive proximal bile duct margin in cases of hilar cholangiocarcinoma.

Ma WJ, Wu ZR, Shrestha A, Yang Q, Hu HJ, Wang JK, Liu F, Zhou RX, Li QS, Li FY.

Hepatobiliary Surg Nutr. 2018 Aug;7(4):251-269. doi: 10.21037/hbsn.2018.03.14.

5.

Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair.

Lamarca A, Barriuso J, McNamara MG, Valle JW.

Cancer Treat Rev. 2018 Sep 8;70:168-177. doi: 10.1016/j.ctrv.2018.09.002. [Epub ahead of print] Review.

PMID:
30218788
6.

Determination of Hepatocellular Carcinoma and Characterization of Hepatic Focal Lesions with Adaptive Multi-Exponential Intravoxel Incoherent Motion Model.

Zhang HX, Zhang XS, Kuai ZX, Zhou Y, Sun YF, Ba ZC, He KB, Sang XQ, Yao YF, Chu CY, Zhu YM.

Transl Oncol. 2018 Sep 11;11(6):1370-1378. doi: 10.1016/j.tranon.2018.08.011. [Epub ahead of print]

7.

Hepatobiliary and Pancreatic: Inflammatory myofibroblastic tumor of the liver mimicking intrahepatic cholangiocarcinoma with hilar lymph node metastasis.

Lu J, Xiong XZ, Cheng NS.

J Gastroenterol Hepatol. 2018 Sep 14. doi: 10.1111/jgh.14444. [Epub ahead of print] No abstract available.

PMID:
30215848
8.

Adrenal metastasis in sequentially developed combined hepatocellular carcinoma-cholangiocarcinoma: A case report.

Nugroho A, Lee KW, Lee KB, Kim HS, Kim H, Yi NJ, Suh KS.

Ann Hepatobiliary Pancreat Surg. 2018 Aug;22(3):287-291. doi: 10.14701/ahbps.2018.22.3.287. Epub 2018 Aug 31.

9.

How to prevent the postoperative pancreatic fistula with an ethylene vinyl alcohol copolymer (Onyx®): A proposal of a new technique.

Crafa F, Esposito F, Noviello A, Moles N, Coppola Bottazzi E, Lombardi C, Miro A, Lombardi G.

Ann Hepatobiliary Pancreat Surg. 2018 Aug;22(3):248-252. doi: 10.14701/ahbps.2018.22.3.248. Epub 2018 Aug 31.

10.

A retrospective review of correlative radiological assessment and surgical exploration for hilar cholangiocarcinoma.

Chua D, Low A, Koh Y, Goh B, Cheow PC, Kam JH, Teo JY, Tan EK, Chung A, Ooi LL, Chan CY, Lee SY.

Ann Hepatobiliary Pancreat Surg. 2018 Aug;22(3):216-222. doi: 10.14701/ahbps.2018.22.3.216. Epub 2018 Aug 31.

11.

Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness.

Xie Y, Wang Y, Li J, Hang Y, Jaramillo L, Wehrkamp CJ, Phillippi MA, Mohr AM, Chen Y, Talmon GA, Mott JL, Oupický D.

Theranostics. 2018 Jul 30;8(16):4305-4320. doi: 10.7150/thno.26506. eCollection 2018.

12.

Diagnostic value of imaging examinations in patients with primary hepatocellular carcinoma.

Li XH, Liang Q, Chen TW, Wang J, Zhang XM.

World J Clin Cases. 2018 Sep 6;6(9):242-248. doi: 10.12998/wjcc.v6.i9.242. Review.

13.

Combined treatment of cholangiocarcinoma with interventional radiofrequency hyperthermia and heat shock protein promoter-mediated HSV-TK gene therapy.

Luo J, Zhou J, Xie F, Zhu Y, Zhou F, Zhang S, Jiang S, He J, Liu J, Wu X, Zhang Y, Sun J, Yang X.

Am J Cancer Res. 2018 Aug 1;8(8):1595-1603. eCollection 2018.

14.

How to Discriminate Between Primary Hepatic Lymphoma and Cholangiocarcinoma.

Yasri S, Wiwanitkit V.

Oman Med J. 2018 Sep;33(5):447. doi: 10.5001/omj.2018.83. No abstract available.

15.

Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma.

He C, Zhang Y, Song Y, Wang J, Xing K, Lin X, Li S.

J Cancer. 2018 Aug 6;9(17):3117-3128. doi: 10.7150/jca.25339. eCollection 2018.

16.

Ivosidenib: First Global Approval.

Dhillon S.

Drugs. 2018 Sep 12. doi: 10.1007/s40265-018-0978-3. [Epub ahead of print]

PMID:
30209701
17.

Necroptosis microenvironment directs lineage commitment in liver cancer.

Seehawer M, Heinzmann F, D'Artista L, Harbig J, Roux PF, Hoenicke L, Dang H, Klotz S, Robinson L, Doré G, Rozenblum N, Kang TW, Chawla R, Buch T, Vucur M, Roth M, Zuber J, Luedde T, Sipos B, Longerich T, Heikenwälder M, Wang XW, Bischof O, Zender L.

Nature. 2018 Sep 12. doi: 10.1038/s41586-018-0519-y. [Epub ahead of print]

PMID:
30209397
18.

Prognostic value of retrieved lymph node counts in patients with node-negative perihilar cholangiocarcinomas.

Lin H, Wu YS, Li Z, Jiang Y.

ANZ J Surg. 2018 Sep 11. doi: 10.1111/ans.14775. [Epub ahead of print]

PMID:
30207026
19.

An Increased Chromosome 7 Copy Number in Endoscopic Bile Duct Biopsy Specimens Is Predictive of a Poor Prognosis in Cholangiocarcinoma.

Kato A, Naitoh I, Miyabe K, Hayashi K, Yoshida M, Hori Y, Natsume M, Jinno N, Asano G, Kato H, Kuno T, Takahashi S, Kataoka H.

Dig Dis Sci. 2018 Sep 12. doi: 10.1007/s10620-018-5280-4. [Epub ahead of print]

PMID:
30206756
20.

Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review.

Lee J, Yoon WS, Koom WS, Rim CH.

Strahlenther Onkol. 2018 Sep 11. doi: 10.1007/s00066-018-1367-2. [Epub ahead of print]

PMID:
30206644

Supplemental Content

Loading ...
Support Center